期刊
HARVARD REVIEW OF PSYCHIATRY
卷 18, 期 5, 页码 293-303出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.3109/10673229.2010.511059
关键词
-
类别
资金
- Intramural NIH HHS [Z99 MH999999] Funding Source: Medline
- NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002857, ZIAMH002828] Funding Source: NIH RePORTER
Mood disorders such as bipolar disorder and major depressive disorder are common, chronic, and recurrent conditions affecting millions of individuals worldwide. Existing antidepressants and mood stabilizers used to treat these disorders are insufficient for many. Patients continue to have low remission rates, delayed onset of action, residual subsyndromal symptoms, and relapses. New therapeutic agents able to exert faster and sustained antidepressant or mood-stabilizing effects are urgently needed to treat these disorders. In this context, the glutamatergic system has been implicated in the pathophysiology of mood disorders in unique clinical and neurobiological ways. In addition to evidence confirming the role of the glutamatergic modulators riluzole and ketamine as proof-of-concept agents in this system, trials with diverse glutamatergic modulators are under way. Overall, this system holds considerable promise for developing the next generation of novel therapeutics for the treatment of bipolar disorder and major depressive disorder.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
© Peeref 2019-2024. All rights reserved.